Jan Kral, MD, PhD, MSc, MBA
@kraljan.bsky.social
Doctor at Charles University and Motol University Hospital, Prague. Ph.D. in colorectal cance. Researcher in obesity, AI, and 3D printing. ESGE Social Media Group. Passionate about GI health and innovation.
💡 AI-assisted peer review is a promising tool, but adoption is fragmented & policies unclear.
🛟Safeguards against bias & breaches are critical.
💡With careful use, AI can enhance productivity while maintaining integrity.
‼️Continuous monitoring is essential! 🔍
🛟Safeguards against bias & breaches are critical.
💡With careful use, AI can enhance productivity while maintaining integrity.
‼️Continuous monitoring is essential! 🔍
December 4, 2024 at 4:45 PM
💡 AI-assisted peer review is a promising tool, but adoption is fragmented & policies unclear.
🛟Safeguards against bias & breaches are critical.
💡With careful use, AI can enhance productivity while maintaining integrity.
‼️Continuous monitoring is essential! 🔍
🛟Safeguards against bias & breaches are critical.
💡With careful use, AI can enhance productivity while maintaining integrity.
‼️Continuous monitoring is essential! 🔍
📰 Key findings from top 100 medical journals:
🔹 78% provide AI peer review guidance.
❌ 59% prohibit AI use, mainly over confidentiality concerns (96%).
✅ 32% allow limited use with conditions like disclosure.
🌐 Global journals are more flexible than US/Europe-based ones.
🔹 78% provide AI peer review guidance.
❌ 59% prohibit AI use, mainly over confidentiality concerns (96%).
✅ 32% allow limited use with conditions like disclosure.
🌐 Global journals are more flexible than US/Europe-based ones.
December 4, 2024 at 4:45 PM
📰 Key findings from top 100 medical journals:
🔹 78% provide AI peer review guidance.
❌ 59% prohibit AI use, mainly over confidentiality concerns (96%).
✅ 32% allow limited use with conditions like disclosure.
🌐 Global journals are more flexible than US/Europe-based ones.
🔹 78% provide AI peer review guidance.
❌ 59% prohibit AI use, mainly over confidentiality concerns (96%).
✅ 32% allow limited use with conditions like disclosure.
🌐 Global journals are more flexible than US/Europe-based ones.
💠Conclusion:
✅Resmetirom is a game-changer for MASH, but precise patient selection is 🔑. Let’s optimize outcomes! 💡
✅Resmetirom is a game-changer for MASH, but precise patient selection is 🔑. Let’s optimize outcomes! 💡
December 1, 2024 at 6:10 AM
💠Conclusion:
✅Resmetirom is a game-changer for MASH, but precise patient selection is 🔑. Let’s optimize outcomes! 💡
✅Resmetirom is a game-changer for MASH, but precise patient selection is 🔑. Let’s optimize outcomes! 💡
💠Results:
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
December 1, 2024 at 6:10 AM
💠Results:
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
🧪 Combination therapy: TNF antagonists + immunomodulators > monotherapy.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
November 30, 2024 at 12:33 PM
🧪 Combination therapy: TNF antagonists + immunomodulators > monotherapy.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
✅ Top therapies: Infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, ustekinumab, risankizumab, and guselkumab.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.
November 30, 2024 at 12:33 PM
✅ Top therapies: Infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, ustekinumab, risankizumab, and guselkumab.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.